Compounds > cyclamin
Page last updated: 2024-11-08

cyclamin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cyclamin: antineoplastic from Ardisia japonica; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441916
CHEMBL ID373379
CHEBI ID3987
MeSH IDM000600045

Synonyms (6)

Synonym
C08938 ,
cyclamin
CHEMBL373379 ,
chebi:3987 ,
Q27106281
DTXSID301318584
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID402882Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by microtiter-tube dilution method1997Journal of natural products, Mar, Volume: 60, Issue:3
Triterpene saponins from Cyclamen mirabile and their biological activities.
AID683329Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
13,28-Epoxy triterpenoid saponins from Ardisia japonica selectively inhibit proliferation of liver cancer cells without affecting normal liver cells.
AID402881Antibacterial activity against Escherichia coli ATCC 25922 by microtiter-tube dilution method1997Journal of natural products, Mar, Volume: 60, Issue:3
Triterpene saponins from Cyclamen mirabile and their biological activities.
AID277219Cytotoxicity against human A549 cell line by MTT assay2007Journal of natural products, Feb, Volume: 70, Issue:2
Biologically active triterpenoid saponins from Ardisia japonica.
AID402893Uterocontractile activity in rat uterus assessed as contraction at 6.5 uM relative to acetylcholine1997Journal of natural products, Mar, Volume: 60, Issue:3
Triterpene saponins from Cyclamen mirabile and their biological activities.
AID683331Cytotoxicity against human HL-7702 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
13,28-Epoxy triterpenoid saponins from Ardisia japonica selectively inhibit proliferation of liver cancer cells without affecting normal liver cells.
AID683330Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19
13,28-Epoxy triterpenoid saponins from Ardisia japonica selectively inhibit proliferation of liver cancer cells without affecting normal liver cells.
AID277218Cytotoxicity against human KATO3 cell line by MTT assay2007Journal of natural products, Feb, Volume: 70, Issue:2
Biologically active triterpenoid saponins from Ardisia japonica.
AID402880Antibacterial activity against Enterococcus faecalis ATCC 29212 by microtiter-tube dilution method1997Journal of natural products, Mar, Volume: 60, Issue:3
Triterpene saponins from Cyclamen mirabile and their biological activities.
AID402879Antibacterial activity against Staphylococcus aureus ATCC 29213 by microtiter-tube dilution method1997Journal of natural products, Mar, Volume: 60, Issue:3
Triterpene saponins from Cyclamen mirabile and their biological activities.
AID277217Cytotoxicity against human HL60 cell line by MTT assay2007Journal of natural products, Feb, Volume: 70, Issue:2
Biologically active triterpenoid saponins from Ardisia japonica.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.98

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.98 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index168.78 (26.88)
Search Engine Supply Index3.98 (0.95)

This Compound (56.98)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
mitomycin
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.		2.110mitomycinalkylating agent;
antineoplastic agent
etoposide
[no description available]		2.0310beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		2.0710aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
beta-escin
[no description available]		2.520
ardisicrenoside a
ardisicrenoside A: isolated from Ardisia crenata; structure in first source		2.4620
ardisiacrispin b
ardisiacrispin B: untero-contracting oleanane triterpene saponin form Ardisia crispa; structure given in first source		2.4620
mirabilin
mirabilin: isolated from tubers of Cyclamen mirabile; mirabilin G (an alkaloid) is also available; structure in first source		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Liver
[description not available]		02.4920
Liver Neoplasms
Tumors or cancer of the LIVER.		02.4920
Benign Neoplasms
[description not available]		02.110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.110